David Kading, OD
Optometrist · Kirkland, WANPI 1013029719
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.3%), consulting fees and gifts — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 28.8% of the total. Reporting peaked in 2022 at $136,721 and has fallen 83.9% since, to $22,078 in 2025. Among optometrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $1153.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$114K
- Carl Zeiss Meditec, Inc.$59K
- AbbVie$53K
- Oculus, Inc.$39K
- Bausch & Lomb Americas Inc.$35K
- Alcon$20K
- plus $78K from 24 others
Across 101 payments — averaging $1190.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$88K
- Bausch & Lomb Americas Inc.$32K
What the payments were for
- Consulting fees$106,57427%
- Speaking & faculty fees$183,53146%
- Grants$10,6253%
- Travel & lodging$15,4904%
- Food & beverage$17,9585%
- Education$6,0002%
- Gifts$38,94310%
- Other$17,6354%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 21 | $114,132 |
| Carl Zeiss Meditec, Inc. | 11 | $58,752 |
| AbbVie(2 entities) | 86 | $52,682 |
| Oculus, Inc. | 12 | $38,615 |
| Bausch & Lomb Americas Inc. | 53 | $34,681 |
| Alcon | 30 | $20,261 |
| Lumenis BE Inc | 2 | $18,150 |
| Kala Pharmaceuticals, Inc. | 17 | $10,801 |
| Shire North American Group Inc | 14 | $8,111 |
| Coopervision Inc. | 14 | $6,635 |
| Eyevance Pharmaceuticals LLC | 3 | $6,321 |
| Thea Pharma Inc. | 9 | $5,875 |
| Novartis | 18 | $5,831 |
| Sun Pharmaceutical Industries Inc. | 18 | $4,219 |
| Tearlab Corp | 5 | $3,950 |
| Dompe US, Inc. | 8 | $2,982 |
| Biotissue Holdings Inc. | 5 | $1,953 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $1,364 |
| Visioneering Technologies, Inc. | 1 | $500 |
| Visionary Optics LLC | 1 | $300 |
| Valley Contax, Inc. | 1 | $200 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Quidel Corporation | 1 | $114 |
| Oyster Point Pharma, Inc. | 2 | $56 |
| Tarsus Pharmaceuticals, Inc. | 1 | $51 |
| Heru, Inc. | 1 | $29 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Sight Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$64,940
- XIIDRA$45,896
- MEIBOMIAN GLAND EVALUATOR$41,563
- CIRRUS HD-OCT$38,606
- Myopia Master$34,239
- MIEBO$32,764
- VUITY$27,480
- optilight$18,150
- CIRRUS 5000 with AngioPlex$17,635
- Tecnis IOL$11,100
- EYSUVIS$10,573
- RESTASIS MULTIDOSE$8,875
- DAILIES$7,400
- Flarex$6,300
- One Series Ultra$5,550
- LUMIGAN$5,150
- MiSight Contact Lens$5,144
- One Series Ultra IOL Delivery System$4,810
- INVELTYS$4,235
- Pentacam AXL WAVE$4,000
How this compares
$396,755 in reported general payments places this provider in the 95th percentile of 1,267 optometrist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 32 | $24,269 |
| XiidraLifitegrast | 11 | $16,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $34,681 | $41,03343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,267 optometrist providers in Washington.
Other optometrist in Kirkland
- Charissa YoungKirkland$11K
- Peter BergenskeOtis Orchards$355K
- Casey ClaypoolSpokane Valley$323K
- Charles ClaytonBellevue$195K
- Herminder BoparaiBellevue$131K
- Rajiv PatelVancouver$118K
- Alan ChousTacoma$115K
- Roya HabibiSeattle$109K
- Bryan HeitmeyerKent$67K
- Kevin OsborneMoses Lake$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.